The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

New Pain-Free Alternative to Biopsy: evaluation, treatment and follow-up options for Hepatitis C patients

Back to News Homepage

Next

Coverage Restrictions for Hepatitis C Drugs

Case Study Suggests Milk Thistle Is Potent Against Hep C

Print this page

Although merely a single case study, evidence for milk thistle (in the right combination, extract and administration method) confirms this herb’s place in Hepatitis C treatment programs.

Case Study in Liver International

The case study being reviewed was published in a February 2015 edition of the journal Liver International. The US-based study evaluated intravenous silibinin in a 44-year-old woman with Hepatitis C genotype 1 who developed a severe psychiatric adverse reaction to a previous course of pegylated interferon and ribavirin (the antiquated standard of care for Hepatitis C). The experimental treatment consisted of combing the following:

  • 1,200 mg/day of silibinin
  • 1,200 mg/day of ribavirin
  • 6,000 iu/day of Vitamin D

After the first three weeks of treatment, the patient’s viral load led to a prediction of achieving a sustained virologic response (the measurement correlated with a cure) in 34 weeks. Provided with this information, the patient agreed to complete 34 weeks of treatment and was rewarded with a sustained virologic response – without any adverse reactions. The authors concluded that silibinin-based therapy is a treatment option for patients who do not respond to or cannot receive other Hepatitis C drugs.

Page 1 2 3

http://www.cancer.gov/cancertopics/pdq/cam/milkthistle/Patient/page2, Milk Thistle (PDQ®), Retrieved April 12, 2015, National Cancer Institute, 2015.

http://www.ncbi.nlm.nih.gov/pubmed/21605016, Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy, Eurich D, et al, Retrieved April 12, 2015, Experimental and Clinical Transplantation, February 2011.

http://www.ncbi.nlm.nih.gov/pubmed/25251042, Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics, Dahari H, et al, Retrieved April 12, 2015, Liver International, February 2015.

23 Comments
Share
Share

Previous

New Pain-Free Alternative to Biopsy: evaluation, treatment and follow-up options for Hepatitis C patients

Back to News Homepage

Next

Coverage Restrictions for Hepatitis C Drugs

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.